We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $335M
1-Year Est. Return 275.57%
This Fund
S&P 500
This Quarter Est. Return
+61.37%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$66.9M
Cap. Flow
-$37.3M
Cap. Flow %
-11.13%
Top 10 Hldgs %
34.76%
Holding
938
New
616
Increased
74
Reduced
90
Closed
134

Top Buys

Rank Stock Value
1
HOOD icon
Robinhood
HOOD
+$16M
2
STM icon
STMicroelectronics
STM
+$13.6M
3
APH icon
Amphenol
APH
+$10.9M
4
STX icon
Seagate
STX
+$7.07M
5
F icon
Ford
F
+$6.02M

Top Sells

Rank Stock Value
1
SNDK
Sandisk
SNDK
+$18.4M
2
LITE icon
Lumentum
LITE
+$14.5M
3
AXTI icon
AXT Inc
AXTI
+$13.3M
4
TSEM icon
Tower Semiconductor
TSEM
+$11.9M
5
MU icon
Micron Technology
MU
+$10.9M

Sector Composition

Rank Sector Weight
1 Technology 38.35%
2 Healthcare 29.66%
3 Financials 6.33%
4 Miscellaneous 6.14%
5 Consumer Discretionary 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPLV icon
101
Invesco S&P 500 Low Volatility ETF
SPLV
$7.14B
$575K 0.17%
+7,680
New +$566K
AVBP icon
102
ArriVent BioPharma
AVBP
$1.53B
$547K 0.16%
15,734
+7,626
+94% +$225K
DNTH icon
103
Dianthus Therapeutics
DNTH
$6.04B
$543K 0.16%
5,571
-1,871
-25% -$163K
CTNM
104
Contineum Therapeutics
CTNM
$637M
$541K 0.16%
+33,037
New +$433K
RGEN icon
105
Repligen
RGEN
$9.52B
$532K 0.16%
+3,902
New +$479K
NOK icon
106
Nokia
NOK
$55.9B
$523K 0.16%
+39,402
New +$507K
NKTR icon
107
Nektar Therapeutics
NKTR
$2.53B
$522K 0.16%
7,481
+1,661
+29% +$122K
SMMT icon
108
CALL
Summit Therapeutics
SMMT
$13.9B
$520K 0.16%
+2,194
New +$38.9K
PHAT icon
109
Phathom Pharmaceuticals
PHAT
$739M
$517K 0.15%
47,663
+20,897
+78% +$238K
MIRM icon
110
Mirum Pharmaceuticals
MIRM
$6.17B
$516K 0.15%
4,404
+824
+23% +$82.7K
ALM
111
Almonty Industries
ALM
$5.01B
$509K 0.15%
+30,733
New +$586K
BCYC
112
Bicycle Therapeutics
BCYC
$300M
$497K 0.15%
117,254
-3,183
-3% -$14.6K
ALKS icon
113
Alkermes
ALKS
$7.78B
$489K 0.15%
9,338
-16,225
-63% -$634K
FLGT icon
114
Fulgent Genetics
FLGT
$537M
$488K 0.15%
+23,793
New +$403K
TENX icon
115
CALL
Tenax Therapeutics
TENX
$70M
$481K 0.14%
+782
New +$9.99K
LQDA icon
116
Liquidia Corp
LQDA
$6.13B
$479K 0.14%
+6,005
New +$322K
ELVN icon
117
Enliven Therapeutics
ELVN
$4.35B
$479K 0.14%
9,433
+2,827
+43% +$120K
TRVI icon
118
Trevi Therapeutics
TRVI
$2.43B
$477K 0.14%
25,601
-2,312
-8% -$33.6K
MANE
119
Veradermics Inc
MANE
$4.12B
$469K 0.14%
3,811
-5,380
-59% -$504K
VRDN icon
120
Viridian Therapeutics
VRDN
$2.58B
$468K 0.14%
+25,490
New +$411K
CYTK icon
121
Cytokinetics
CYTK
$10.1B
$455K 0.14%
+5,346
New +$384K
AVTX icon
122
Avalo Therapeutics
AVTX
$1.03B
$454K 0.14%
24,544
+16,626
+210% +$263K
ALMS
123
CALL
Alumis Inc
ALMS
$1.44B
$444K 0.13%
508
+255
+101% +$5.93K
NWS icon
124
News Corp Class B
NWS
$18.3B
$444K 0.13%
15,810
-17,866
-53% -$531K
MGNX icon
125
MacroGenics
MGNX
$282M
$441K 0.13%
95,371
-56,357
-37% -$213K
3 4
5
6 7

Similar funds

JWM
Jessup Wealth Management Dayton, Ohio $335M AUM 56.2% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $335M AUM 97.32% 1-Year Est. Return
TFA
TPG Financial Advisors Portland, Oregon $335M AUM 14.14% 1-Year Est. Return
SIM
Seaview Investment Managers Miami, Florida $335M AUM 47.2% 1-Year Est. Return
OWM
OneAscent Wealth Management Birmingham, Alabama $336M AUM 20.38% 1-Year Est. Return
SS
Spinecap SAS Paris, France $335M AUM 16.94% 1-Year Est. Return
BIA
BHK Investment Advisors Birmingham, Alabama $335M AUM 20.89% 1-Year Est. Return
ATC
Adirondack Trust Company Saratoga Springs, New York $336M AUM 29.2% 1-Year Est. Return

Persistent Asset Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Persistent Asset Partners held 938 positions worth $335M, up 25% from $268M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Persistent Asset Partners withdrew a net $37.3M in Q2 2026, closing 134 positions and reducing 90 holdings. Its most notable exit was Lumentum, an estimated $14.5M position sold in full.

By sector, the portfolio is most concentrated in Technology at 38% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Persistent Asset Partners opened a new position in Robinhood worth $19.2M.

  • Persistent Asset Partners's largest Q2 2026 buy was Robinhood: 191,095 shares worth $19.2M.
  • Persistent Asset Partners added most to United Therapeutics in Q2 2026, an estimated $3.99M increase.
  • Persistent Asset Partners's biggest Q2 2026 reduction was Sandisk, cutting an estimated $18.4M.
  • Persistent Asset Partners fully exited Lumentum in Q2 2026, selling an estimated $14.5M.
  • Persistent Asset Partners's ten largest holdings make up 35% of its $335M portfolio in Q2 2026.
  • Persistent Asset Partners opened 616 new positions and closed 134 in Q2 2026.
  • Persistent Asset Partners's portfolio value rose 25% quarter-over-quarter to $335M.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.